Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity

Canaud B et al. Dialysis sickness-dialysis related morbidity
Abstract
The development of maintenance hemodialysis (HD) for end stage kidney disease patients is a success story that continues to save many lives. Nevertheless, intermittent renal replacement therapy is also a source of recurrent stress for patients. Conventional thrice weekly short HD is an imperfect treatment that only partially corrects uremic abnormalities, increases cardiovascular risk and exacerbates disease burden. Altering cycles of fluid loading associated with cardiac stretching (interdialytic phase) and then fluid unloading (intradialytic phase) likely contribute to cardiac and vascular damage. This unphysiologic treatment profile combined with cyclic disturbances including osmotic and electrolytic shifts may contribute to morbidity in dialysis patients and augment the health burden of treatment. As such, HD patients are exposed to multiple stressors including cardiocirculatory, inflammatory, biologic, hypoxemic and nutritional. This cascade of events can be termed the dialysis stress storm and sickness syndrome (D4S). Mitigating cardiovascular risk and morbidity associated with conventional intermittent HD appears to be a priority for improving patient experience and reducing disease burden. In this in-depth review, we summarize the hidden effects of intermittent HD therapy, and call for action to improve delivered HD and develop treatment schedules that are better tolerated and associated with fewer adverse effects.

Key Words: End stage kidney disease; Cardiovascular mortality; Dialytic morbidity; Circulatory stress; Biologic storm; Dialysis sickness; Personalized medicine


Core Tip: In this in-depth review, we summarize the hidden effects of intermittent hemodialysis (HD) therapy namely dialysis sickness and dialysis related morbidity. We
call for action to improve delivered HD and develop treatment schedules that are better tolerated and associated with fewer adverse effects. The final aim is intend to reduce cardiovascular burden and improve patients outcomes.

INTRODUCTION

Conventional hemodialysis (HD) is a mature treatment that sustains life in almost 3 million patients with end stage kidney disease (ESKD) worldwide and provides a valuable bridging solution to kidney transplant\textsuperscript{[1-4]}. However, by nature intermittent HD is an imperfect treatment that only partially corrects uremic abnormalities, increases cardiovascular risk and is associated with a high disease burden\textsuperscript{[5-11]}. The high treatment costs of renal replacement therapy represent in addition a significant health economic burden\textsuperscript{[12-14]}. Recent evidence indicates that conventional high efficiency thrice-weekly intermittent HD schedules may be harmful to patients by provoking alternating cycles of fluid loading associated with cardiac stretching during the interdialytic period and fluid unloading that contribute to cardiac and vascular damage. This unphysiologic loading and unloading phenomenon combined with cyclical disturbances including osmotic and electrolytic shifts may contribute to dialytic morbidity and augment the health burden associated with the treatment of uremia\textsuperscript{[15-17]}. Over past few years, several studies have emphasized the importance of ensuring optimal fluid volume and arterial pressure control, as well as adequately dosed and better tolerated dialysis therapy to improve patient outcomes\textsuperscript{[18]}. The benefits of a dry weight first policy approach has been reinforced by interventional studies\textsuperscript{[19-21]}. Fluid volume guidance has also been facilitated by means of supportive tools\textsuperscript{[22-24]}. On the other hand, prospective clinical studies have documented that intermittent treatment might cause significant circulatory stress depending on treatment time and schedule\textsuperscript{[10,25-27]}, but have also shown that guided interdialytic and/or specific dialysis-based interventions might be able to reduce this risk\textsuperscript{[10,28,29]}. 3 / 19
However, few reports have focused on all aspects of dialysis patient management in a comprehensive way. In this in-depth review we summarize potential harmful effects of intermittent HD and propose solutions for achieving more cardioprotective and tolerable treatment.

**INTERMITTENT EXTRACORPOREAL RENAL REPLACEMENT THERAPY IS THE SOURCE OF PERMANENT STRESS IN MAINTENANCE HD PATIENTS**

*Cardiocirculatory stress*

The ‘unphysiology’ of intermittent HD is recognized as a leading cause of dialysis intolerance and multiorgan morbidity. This phenomenon was exacerbated by operational changes that resulted in shortening of dialysis treatment schedules and increasing dialysis efficiency. As such, intermittent HD generates periodic changes in volume and blood pressure, osmotic shifts, and variation in circulating levels of compounds and electrolytes. Treatment-induced disturbances are in complete contrast with strictly regulated and stable conditions of the internal milieu in healthy subjects. (Figure 1)

During the interdialytic period, anuric HD patients tend to accumulate sodium and fluid according to fluid and diet intake leading to chronic fluid overload. In this condition, fluid overload has two components: The first, resulting from cyclic changes imposed by intermittent treatment marked by weight gain, progressive increase of systemic arterial pressure and pulmonary arterial pressure with cardiac stretching occurring between two treatment sessions; the second, that reflects chronic fluid overload that has accumulated over time exposing patients to chronic cardiac stretching and structural cardiac remodeling. (Figure 1)

During the intradialytic period, sodium and fluid removal resulting from ultrafiltration (intradialytic weight loss) and the patient to dialysate sodium gradient contribute to reduce circulating blood volume and trigger an adaptative hemodynamic response. In response to ultrafiltration provoking a reduction in blood volume and cardiac stroke volume, arterial pressure and tissue perfusion are maintained by an
increase in vascular tone, mainly through vasoconstriction of alpha-adrenoceptor territories, and an increase of vascular refilling and in venous return\textsuperscript{[42,43]}. Recent intradialytic imaging studies have shown that reduction in myocardial perfusion and contractility (myocardial stunning) are linked to ultrafiltration rate that happens even without ischemic cardiac disease\textsuperscript{[17,44,55]}. Several observational studies have reported a strong association between mortality and high ultrafiltration rate or volume changes, drop in blood pressure and end-organ ischaemic insult\textsuperscript{[30]}. The systemic response is more complex than a simple reaction to hypovolemia, since it encompasses other factors such as vascular refilling capacity, thermal balance, electrolyte fluxes, nutrient losses, as well as the individual patient’s baseline cardiac reserve and neurohormonal stress responses\textsuperscript{[45,46]}. Interesting, this response may be mitigated by various factors (e.g., age, gender, comorbidity, medication) explaining individual or temporal variations in hemodynamic response\textsuperscript{[38,47]}. The hemodynamic stress induced by dialysis must be considered as a potent disease modifier in highly susceptible patients\textsuperscript{[48]}. (Figure 1)

Whatever the exact contribution of these phenomena, dialysis-induced cyclical volemic changes (hyper- and hypovolemia) that provoke alternating cardiac loading and unloading. This volemia variation cycle is responsible for repetitive myocardial stretching, a mechanism that leads to release of inflammatory mediators and promote cardiac fibrosis and arrhythmias\textsuperscript{[49,50]}. (Figure 1)

\textbf{Inflammatory stress}

Bio-incompatibility (or more specifically, hemo-incompatibility) of the extracorporeal blood circuit and its systemic effects is a well identified issue associated with several aspects of dialysis related morbidity\textsuperscript{[51,52]}. In brief, the activation of a cascade of serum proteins and blood cells is induced upon contact with foreign material in the extracorporeal circuit\textsuperscript{[53,54]}, and endothelial damage may further induce a vascular endothelial breach\textsuperscript{[55]}. This process is further modified by the geometry, design (e.g., blood air interface, dead space), and nature of blood tubing (e.g., type of polymer, plasticizer) or dialyzer membrane (e.g., cellulosic, synthetic), and may be amplified by
microbial-derived products from dialysis fluid (e.g., Lipopolysaccharide, endotoxins, bacterial DNA)[56-59]. As a result, endothelial cells and circulating blood cells (e.g., platelets, leukocytes, monocytes) are primed and activated to release pro-inflammatory mediators (e.g., platelet activating factor 4, beta-thromboglobulin, granulocytes proteinases, anaphylatoxins, cytokines) and activate protein cascades (e.g., clotting cascades, complement activation, surface contact, kalikrein-kinin system)[60-66].

Activation of the innate immune and coagulation systems amplifies and propagates this reaction[67]. Platelets and endothelial cell activation trigger coagulation, endothelial damage, vascular reactivity and pulmonary trapping of cells. Mononuclear leukocyte activation results in the release of enzymes (e.g., granulocyte neutral proteinase, elastase)[60,68-70], and increases their reactivity and adhesiveness that may cause obstruction at the microcirculatory level. In the lungs, this may contribute to hypoxemia[71-73]. Activation of monocytes and macrophages induces release of proinflammatory cytokines [interleukin (IL)-1, IL-6, tumor necrosis factor-α][74,75]. In addition, acute inflammatory reactions are amplified by oxidative stress in an amplifying loops contributing to a vicious circle[74]. Seminal studies performed in various HD settings (e.g., cellulosic vs synthetic dialyzers, contaminated vs ultrapure dialysate) have documented the importance of this “biologic storm” and provided evidence of its damaging effects (e.g., allergic reaction, lung dysfunction, thrombocytopenia, inflammation)[67,76], (Figure 1)

Despite significant improvements in extracorporeal circuit biocompatibility and wide-spread use of ultrapure dialysis fluid, systemic hemobiological reactions periodically induced by extracorporeal treatment[77,78] are likely to contribute to a micro-inflammatory state in chronic HD patients that amplifies long-term deleterious effects[30,75,79], (Figure 1)

**Biological stress**

In the absence of significant kidney function, internal metabolic processes and dietary intake produce metabolites during the interdialytic phase that steadily accumulate over
48 h and lead to classical biologic uremic abnormalities\[60\]. During dialysis, biologic disorders are usually corrected, at least partially, within 4 h. Biologic gradients between the dialysate and blood may be large, resulting in high amplitude changes of body composition during each session\[32,76,81,82\]. This gradient stress may be easily quantitated by dialysate-blood gradient concentrations and time averaged deviations for various solutes that are exchanged during the dialysis session\[81\]. Solutes exchange in HD follow negative or positive gradients, knowing that solute gradient is conventionally defined as dialysate-plasma concentration difference. Uremic retention toxins (e.g., urea, creatinine, uric acid, potassium, phosphate) are removed according to a negative gradient from blood to dialysate, while selected electrolytes (e.g., bicarbonate, calcium, magnesium) or nutritional compounds (e.g., glucose) may move in the opposite direction. Unwanted removal of essential nutrients (e.g., amino acids, peptides, water soluble vitamins such vitamin D) and albumin may occur contributing to a nutritional stress. The description of biochemical changes during dialysis is beyond the scope of this review. Through this remark we emphasize the fact that dialysis patients are challenged by various and large osmotic changes due to movements of urea and uraemic metabolites, water shift from extra to intracellular, acid-base changes moving the patient from metabolic acidosis to mixed alkalosis, potassium swings from hyper- to hypokalemia, divalent ion alterations moving from hyper- to hypophosphatemia and from hypo- to hypercalcemia, while at the same time patients are losing amino-acids and other important nutrients\[83-86\]. Clinical manifestations of these metabolic derangements range from none, through minor to severe symptoms (fatigue, headache, cognitive impairment), with the most extreme manifestation being dialysis disequilibrium syndrome\[87,88\]. (Figure 1)

**Hypoxemic stress**

During dialysis, in addition to circulatory stress and impaired tissue perfusion\[89-91\], hypoxemia may occur, which can be particularly marked in the early phase of a dialysis session, likely related to hemoincompatibility reactions inducing leukocyte trapping
within the lungs. This observation suggests the occurrence of an additional respiratory stress resulting from impaired pulmonary gas exchange\textsuperscript{[92,93]}. Prolonged intradialytic hypoxemia is likely to play an aggravating role in end organ damage by reducing further tissue oxygen delivery. We can speculate that this is a pathophysiologic link that explains the increased mortality observed in patients presenting with prolonged hypoxemia during HD\textsuperscript{[92]}. (Figure 1)

During the interdialytic phase, sleep apnea syndrome (SAS) and nocturnal hypoxemia have emerged as important additional cardiovascular risk factors in HD patients\textsuperscript{[80]}. SAS marked by repetitive pause of breathing during sleep resulting in hypoxemia and hypercapnia is highly prevalent in HD patients\textsuperscript{[80,94]}. In addition, SAS is associated with profound changes in cardiac loading conditions, lung arterial pressure and autonomic activation, all factors that have been associated with significant cardiovascular morbidity such as left ventricular hypertrophy or arrhythmias and sudden cardiac death\textsuperscript{[95-98]}. Although uremic abnormalities contribute to the development of SAS, the role of fluid overload exacerbating upper airways obstruction should not be neglected as recently pointed out by a study exploring fluid displacement into nuchal and periharyngeal soft tissues in healthy subjects\textsuperscript{[99]}. It is therefore tempting to speculate that chronic fluid overload is partly responsible for an edema of upper airway especially during sleep while in the supine position, thereby contributing to the occurrence of SAS. (Figure 1)

In brief, whatever mechanisms are associated with impaired pulmonary gas exchange in HD patients, occurring either during intradialytic or interdialytic phases, prolonged periods of hypoxemia are likely to represent an additional stressor\textsuperscript{[34]}. (Figure 1)

\textit{Nutritional stress}

Loss of muscle mass is common in HD patients and represents one of the most important predictors of mortality\textsuperscript{[100,101]}. Sarcopenia is the main component of the
protein-energy wasting syndrome that results from complex uremic abnormalities and the adverse effects of HD treatment\textsuperscript{102-104}. (Figure 1)

On one hand, acute studies assessing muscle and whole body protein turnover conducted in stable patients have consistently demonstrated an imbalance in protein synthesis and degradation during HD sessions\textsuperscript{105-108}. It has been also shown that losses of amino acids during HD, ranging between 8 and 10 g per session, contributed significantly to the net protein catabolism\textsuperscript{85,109-111}. Interestingly, this amino acid loss leads to reprioritization of protein metabolism during HD sessions. Amino acid loss during HD stimulates muscle and liver protein catabolism in order to preserve plasma and intra-cellular amino acid concentrations. Furthermore, aminoacid utilization for protein synthesis either by liver or muscle is impaired in HD patients, mainly through activation of cytokine pathways (IL-6) rather than because of amino acid depletion\textsuperscript{112-114}. Remarkably, amino acid repletion by IV administration during HD tends to increase muscle protein synthesis but does not decrease muscle protein breakdown\textsuperscript{115}. It is also interesting to note that dextrose depletion (when dextrose-free dialysate is used)\textsuperscript{116}, and other aspects of HD including type of membrane (cellulosic vs synthetic)\textsuperscript{117,118} and dialysate microbiologic purity\textsuperscript{119,120} may modulate this muscle protein catabolism phenomenon\textsuperscript{121}. (Figure 1)

On the other hand, long-term precise nutritional studies conducted in stable patients under strict metabolic conditions have shown that HD-induced imbalance in protein metabolism\textsuperscript{122,123} might be compensated for by dietary protein and caloric supplements\textsuperscript{124,125}. As shown, the net negative protein metabolic imbalance observed on dialysis days might be compensated for by increasing dietary protein and caloric intake (about 25\%) during non-dialysis days, leading to a neutral protein and caloric balance on a weekly basis\textsuperscript{124,126}. However, in practice, this can be hard to achieve.

In brief, intermittent HD treatment is associated with repetitive nutritional stress conditions due to reprioritization of protein metabolism within muscle and liver. (Figure 1)
**Dialysis sickness and dialysis related morbidity**

Dialysis sickness (DS) refers to the concept that inter-, peri- and intradialytic morbidity resulting from the hemodynamic, inflammatory, biological, hypoxemic and nutritional stresses discussed above, can result in the long-term in end organ damage as summarized in Figure 2.

Dialysis-related morbidity (intra and peridialytic symptomatology) has a negative impact on patients’ perception and on their quality of life (QoL)\[^{16,48,93,127,128}\]. This can be measured by scoring scales according to patient reported outcomes measures (PROM) or patient reported experience measures (PREM)\[^{129-131}\]. Intra and interdialytic symptoms that include hypotensive episodes, cramps, headache, fatigue, pruritus, and sleep disorders are the most frequently reported\[^{132}\]. PROMs, PREMs and most domains of health related QoL are significantly reduced in patients treated by conventional HD and tend be improved by daily or extended treatment schedules\[^{133-135}\]. Furthermore, dialysis symptom burden has been shown to be associated with increased mortality and hospitalization risks. Indeed, these clinical performance indicators are strongly recommended to assess dialysis adequacy and patient experience\[^{129,136-139}\]. (Figure 1)

End organ damage results from exposure to hemodynamic and pulmonary stressors leading to poor tissue perfusion and oxygen delivery, which are further aggravated by biological and cytokine “storms”. Multifactorial and repetitive systemic stressors induced by intermittent HD treatment are likely to have harmful long-term effects on the function and structural modeling of vital organs (e.g., cardiac stunning, leukoaraiosis, gut ischemia, hepato-splanchnic changes). Some of these cardiovascular effects are enhanced by chronic low-grade inflammation acting on endothelial dysfunction and contributing to poor outcomes\[^{10,28,140-142}\]. The combination of cardiocirculatory stress, hypovolemia and electrolyte changes occurring during HD sessions creates pro-arrhythmogenic conditions that may contribute to clinically significant cardiac arrhythmias during the interdialytic phase\[^{143-147}\]. Cardiac structural changes following myocardial stunning, and remodeling in response to cyclical dialysis-induced phenomenon, such as fibrotic scarring and loss of segmental
contractile function with irregular electrical conductivity are plausibly increasing the risk of sudden cardiac death\textsuperscript{[14,146,148-151]}. These findings mimick the intense physiologic demands endured by healthy subjects under extreme conditions\textsuperscript{[152]}. In order to mitigate dialysis-induced organ damage, we propose that conventional HD treatment schedule may be adapted and personalized, as a new treatment paradigm.

**CALL FOR DESIGNING AND APPLYING A MORE CARDIOVASCULAR PROTECTIVE HD TREATMENT**

*Optimizing hemodynamic management*

The inevitable sodium and fluid accumulation that occurs during the interdialytic phase in anuric HD patients is responsible for chronic extracellular fluid overload with its adverse effects\textsuperscript{[153,154]}. Hypertension is part of this constellation of disorders being recognized as the leading cause of cardiac and vascular disease in HD patients\textsuperscript{[19,20]}. Management of fluid volume has been identified as a specific cardiovascular risk factor. On one hand, persistence of chronic fluid overload is independently associated with increased cardiovascular risk\textsuperscript{[155]}; on the other hand, overly-rapid fluid volume reduction (i.e., ultrafiltration rate) and hypovolemia is also associated with an increased risk of cardiovascular mortality\textsuperscript{[10,156]}. (Figure 3)

In other words, sodium and fluid volume homeostasis and blood pressure need to be managed more precisely during the interdialytic phase to achieve suitable targets. Additionally, hemodynamic stress secondary to volume contraction should be mitigated during dialysis by the use of appropriate tools and adjustment of the treatment schedule. Better monitoring of blood pressure and haemodynamics that are applicable to the clinical setting are also needed. This is a fundamental challenge of intermittent HD. (Figure 3)

**Improving sodium, fluid volume and pressure management during the interdialytic phase:** Salt and fluid management of the dialysis patient represents a major challenge for clinicians. A combined approach is needed that includes clinical management (a dry
weight probing policy e.g., ultrafiltration, dialysate sodium prescription, diet education supported by assessment tools (e.g., multifrequency bioimpedence, lung ultrasound)[157], cardiac biomarkers [e.g., B-type natriuretic peptide (BNP), NTproBNP], HD technical options (e.g., sodium control module) and algorithms (e.g., artificial intelligence) using advanced analytics in the future[38,158]. (Figure 3)

**Reducing hemodynamic stress induced by HD:** Intradialytic morbidity (i.e., fatigue, headache, cramps, hypotension, alteration of cognitive function) is largely dependant on fluid removal (i.e., ultrafiltration) and dialysis efficiency (i.e., osmotic and solute concentration changes, electrolytes shifts). The intensity and frequency of these symptoms also depends on patient characteristics (e.g., age, gender, anthropometrics), metabolism and body composition, and on the HD treatment schedule (e.g., treatment time and frequency). It is well recognized that longer and more frequent dialysis treatment schedules are better tolerated with reduced circulatory stress and slower osmotic and electrolytic changes, as compared to short and less frequent dialysis schedules[159,160]. In that respect ultrafiltration rate, reflecting fluid volume removed per time unit, is a well recognized cardiac risk factor in dialysis patients that also associates with mortality risk[40]. In addition, it reflects the fact that biochemical gradients and solute fluxes are reduced per time unit, as well as osmotic changes and water shifts occurring within the central nervous system. (Figure 3)

In a stepwise approach, increasing treatment time and/or dialysis frequency should ideally represent the first and most rational step to reduce risks associated with ultrafiltration rate and osmotic changes in non-compliant or fragile patients[161]. As a next step, modulating patients’ hemodynamic responses through various tools embedded in the HD machine is another appealing option[162]. Monitoring blood volume during dialysis sessions is useful to identify critical volemicia, to estimate remaining fluid in the interstitium or to quantify vascular refilling capacity[163], but it is not sufficient to manage patient hemodynamic response[164]. Instead, surveillance of central venous oxygen saturation (ScvO2) in patients with central venous catheters may
indicate critical changes in organ perfusion before they result in clinical symptomatology. Interestingly, the decline in ScvO2 during dialysis has been correlated to ultrafiltration volume\cite{165,166}. With arterio-venous fistula, near infrared spectroscopy, a non-invasive method, could be of interest to estimate tissue oxygenation\cite{167}. Feedback controlled ultrafiltration system relying on blood volume changes has improved hemodynamic stability in selected studies, but so far has not improved patient outcomes and intradialytic morbidity\cite{168,169}. Some studies have shown that using dialysate sodium and ultrafiltration profiling, with or without blood volume monitoring, may preserve intradialytic hemodynamic status but at the expense of increased risk of subclinical salt loading, thirst, high interdialytic weight gain and chronic fluid overload\cite{170}. Adjusting dialysis thermal balance to preserve peripheral vascular resistance and cardiac output is also a simple strategy to improve hemodynamic tolerance that has been proven effective in several studies\cite{171}. The main objective is to deliver isothermic or better, hypothermic dialysis, to prevent thermal gain during a dialysis session which is associated with an inappropriate hemodynamic response (vasodilation, tachycardia, drop in ejection fraction)\cite{172}. Hypothermic HD could be manually achieved by setting dialysate temperature 0.5-1 °C below the patient’s core temperature. Automated thermal control of dialysis sessions requires the use of an online blood temperature monitor (blood temperature monitor) that can control precisely the thermal balance of patients to a preset target\cite{173}. Both approaches reduce hypotension incidence. (Figure 3)

Another important component of intradialytic morbidity relates to biochemical stress as reflected by the magnitude of dialysate-plasma solute gradient, a major determinant of solute fluxes\cite{170,174,176}. Reducing instantaneous solute fluxes while keeping solute mass removal constant during dialysis session may be an interesting approach reduce intradialytic morbidity. This issue could be easily addressed by reducing blood flow and increasing treatment time and/or frequency to slow instantaneous solute fluxes. This is a usual practice in Japan but it is not the most popular nor the most appealing in Western countries\cite{177}. Another approach within the current short dialysis treatment
schedule would be to continuously adjust flow parameters to reduce instantaneous solute fluxes while keeping solute mass transfer constant. Advanced technology will facilitate such an approach in the future, relying on microsensors positioned on dialysate side, feeding specific algorithms and then providing feedback control to the HD monitor to adjust relative flows and gradients. (Figure 3)

In summary, one should consider that fluid volume removal and solute fluxes (dependent in part on blood-dialysate concentration gradients) are potentially modifiable factors of the dialysis prescription. (Figure 3)

**Enhancing renal care efficacy**

The limited efficiency of contemporary HD in restoring the internal milieu composition and in controlling circulating levels of middle and large molecular sized uremic toxins, has stimulated use of convective-based therapies (e.g., hemodiafiltration) and more porous membranes (i.e., high cut-off)\(^\text{[36]}\). Therefore, the so call ‘residual syndrome’, reflecting incomplete removal of uremic toxins, is another potential contributor to patient morbidity and mortality\(^\text{[178,179]}\). (Figure 3)

Enhancing treatment efficiency by combining high efficiency hemodiafiltration and extended treatment time has been shown in recent studies to be able to address most remaining issues in adults. In brief, extended on-line hemodiafiltration (HDF) treatment has been associated with tight control of fluid volume and blood pressure without antihypertensive medications, normalization of phosphate levels while phosphate binders were stopped, correction of anemia while erythropoeitic stimulating agent consumption was reduced by 50\% and with a significant improvement of nutritional status and physical activity\(^\text{[180,181]}\). Interestingly, in a pediatric population extended HDF has been also shown to improve intermediary outcomes (i.e., fluid volume, blood pressure, inflammation, phosphate, nutrition), to reduce cardiovascular disease progression and to promote catch-up growth\(^\text{[182-184]}\). (Figure 3)

Preserving residual kidney function is an important feature in dialysis patients since it is associated with a reduced disease and treatment burden and mortality\(^\text{[185-187]}\). Fluid
volume and blood pressure control are usually better achieved with less dietary restriction[188]. Circulating levels of uremic toxins are significantly reduced, particularly for middle and large molecular weight substances but also for protein-bound uremic toxins[189]. In brief, all dialysis conditions, but particularly those ensuring a better hemodynamic stability should be considered to prevent the repetitive ischemic kidney insults during HD[190]. (Figure 3)

Acting on the gut to reduce protein-bound uremic toxin production has been recently suggested as a potential way of reducing circulating levels of protein bound uremic toxins (PBUT) such as indoxyl sulfate and paracresyl sulfate[191]. A few studies have confirmed positive effects of this option using either probiotics or adsorbers (AST120) administered orally in reducing plasma PBUT concentrations[192,193]. Unfortunately, published interventional studies have not confirmed potential long-term clinical benefits on patient outcomes[194] but further studies with better design and greater statistical power are warranted. (Figure 3)

**Personalizing renal replacement treatment schedule**

**Treatment schedule adaptation:** A ‘one size fits all’ approach is unlikely to work, and this should be kept in mind for optimizing renal replacement therapies in the future. Accordingly, dialysis prescription including treatment schedule (time and frequency), modality, dose and efficiency[134,195,196], and electrolyte prescription should be tailored to patient profile, needs and tolerance[197,198]. Furthermore, treatment prescription should be adapted over time to an individual patient’s results in a personalized way to follow patient metabolic changes, treatment tolerance, and symptoms. Dialysis prescription should return to physiologic principles; it should not be the patient who must adapt to a fixed treatment, but the treatment should fit to the patient needs and tolerance instead.

In this context, the treatment schedules offered to patients should be expanded and become more flexible. It is not our intent to develop this concept further but to highlight recent interesting findings. (Figure 3)
Incremental dialysis is an interesting concept that deserves more attention in particular in incident ESKD patients and in emerging countries[199]. It relies on the fact that HD acts as a complement to residual kidney function. In other words, the number of dialysis sessions and/or treatment time per week is inversely related to the glomerular filtration rate. Recent comprehensive reviews have addressed this issue to which we refer the interested reader for more details on clinical benefits and implementation[200]. In brief, incremental dialysis has the capacity to facilitate treatment implementation in new patients by reducing treatment burden, but also potentially to mitigate a shortage of renal replacement therapy resources in low and middle income countries. (Figure 3)

Extended HD schedules (i.e., long and nocturnal dialysis, alternate day dialysis, daily HD) appear particularly attractive in terms of improving outcomes[181]. Extended treatment schedules must be viewed from two aspects: On one hand, outcomes compare favorably including with kidney transplant[195,201-204]; on the other hand, they increase treatment burden and cost, except if home HD is chosen[205]. In this context, to solve both logistical and cost issues, it is therefore proposed to develop extended treatment schedules at home or in self-care facilities[206]. (Figure 3)

**Use of new tools for monitoring and adapting treatment prescription:** A whole body bioimpedance cardiography (BIC) non-invasive device has been assessed in HD patients. BIC has interesting features to measure the hemodynamic response to fluid removal (e.g., cardiac output, total peripheral vascular resistance) during dialysis. Based on these findings, it has been suggested that dialysis patients might be clustered into various categories defined as low or high cardiac output, low or high total peripheral vascular resistance or normal hemodynamics[207,208]. BIC has the potential to support physicians to individualize dialysis treatment, although this would need to be tested in interventional studies[208]. Approaches using BIC warrant further studies to validate measurements and explore impact on patient outcomes[209]. (Figure 3)
More recently, lung ultrasononography (LUS) has been proposed as a point-of-care tool to complete physical examination\cite{24,210,211}. Lung ultrasound is a noninvasive method to estimate extravascular lung water easily mastered by nephrologists that help to quantify lung congestion by counting B-lines per lung area unit (Comet line scoring). The “Lung water by Ultra-Sound guided Treatment to prevent death and cardiovascular complications in high risk ESRD patients with cardiomyopathy” study has shown the clinical value of LUS in the management of HD patients at high cardiovascular risk\cite{212,213}. (Figure 3)

A further tool to reduce intradialytic hemodynamic stress is the development of wearable non-pervasive methods for continuous blood pressure monitoring. This would allow detection of subtle changes in blood pressure to prompt interventions such as reduction of ultrafiltration rate to prevent hypotension. Recent work using additional pressure sensors placed on dialysis lines to derive blood pressure without the need for additional equipment attached to the patient, shows promise in this regard\cite{214,215}. Considering the high cardiac mortality risk of HD patients (10 to 100 times greater than the general population)\cite{216}, it appears of utmost importance to pay closer attention to cardiovascular monitoring to ensure early and appropriate intervention for improving outcomes\cite{49}. Interestingly, new remote technologies or so called connected ihealth devices offer convenient new tools for monitoring high risk HD patients during the interdialytic period in a fully automated and ambulatory mode\cite{217}. Detection of clinical significant arrhythmias would be one important functionality, as shown in recent studies\cite{146,218}. (Figure 3)

**FUTURE DEVELOPMENT OF HD AND RENAL REPLACEMENT THERAPY**

In order to reduce dialysis associated morbidity and to improve patient experience, three main approaches should be proposed and explored.

*Designing and adapting HD treatment schedule to individual patient needs, tolerance and risks*
Aside from the introduction of more flexible treatment schedules, recent studies have also shown the potential interest of stratifying patients according to their risks at short or medium term outcomes\cite{219,220}. Better understanding of patient risks could help physicians to prescribe more appropriate and individualized therapy. Also, scoring systems could be tested as supports to alter specific treatment prescription features in an attempt to reduce early mortality of ESKD patients transitioning to dialysis.

Using automated systems embedded in intelligent dialysis machines
The technology relies on the combination of patient biologic sensors coupled to a feedback control loop and governed by adaptive algorithms embedded in the dialysis machine. The first example is the sodium control module that has been assessed and validated in clinical trials\cite{221}. Using continuous conductivity cell measurements on inlet and outlet dialysate flow, an embedded algorithm controls plasma sodium concentration changes (i.e., tonicity) and allows precise monitoring of plasma sodium concentration and sodium mass removal occurring within dialysis session. Interestingly, sodium mass transfer and plasma tonicity rely on an automated and self-adapting function that follows medical prescription setting. Further outcome based studies are needed to establish clinical benefits to patients and the device’s clinical added value\cite{222}.

Combining use of connected ihealth devices, advanced analytics and artificial intelligence will be able to support medical decision making and to predict future outcome
Personalized medicine relying on ihealth trackers, advanced analytics and artificial intelligence (artificial neuronal networks, machine learning) may allow identification of patients at increased risk. In this respect, the use of such tools will be able to support physician decision-making for individual patients to select the most appropriate treatment modality or suitable technical approach (i.e., ultrafiltration rate, dialysate sodium) to reduce cardiovascular burden\cite{223,224}. Furthermore, ihealth trackers and
machine learning support may also be applied to continuous vital signs monitoring and other intra-dialytic hemodynamic variables. The ultimate goal is to detect or predict the occurrence of future clinical events with sufficient precision and time to intervene. Such ihealth trackers seems particularly attractive to monitor arrhythmias and maybe to help prevent sudden cardiac death[217]. In brief, the paradigm of precision medicine appears particularly relevant to renal replacement therapy for designing a personalized, more effective, better tolerated and more acceptable HD treatments[228].

CONCLUSION
In this in-depth review, we have summarized factors that are implicated in the cardiovascular and multi-organ morbidity associated with conventional short intermittent HD treatment schedules. Hidden risks result mainly from the conjunction of two main phenomena: First, the intermittent nature of the treatment that is responsible for an unphysiologic profile (illustrated by peaks and troughs reflecting fluctuation of internal milieu composition) and a multifactorial systemic stress; second, the incomplete correction of uremic metabolic abnormalities that may be summarized as “residual syndrome”. Such systemic stress induced by HD treatment is likely implicated in the poor dialysis tolerance and end-organ injury contributing to the DS syndrome. We summarize this cascade of events as the “Dialysis Storm, Stress, and Sickness Syndrome” (D4S) and propose that D4S may act as a negative disease modifier of patient outcome.

Mitigating cardiovascular burden in HD requires further concerted actions to change the treatment paradigm. Such an approach will have multiple targets that should ideally include optimizing hemodynamic management both during the inter- and intra-dialytic phase, enhancing renal replacement therapy efficacy and personalizing treatment schedule with use of new monitoring tools.
<table>
<thead>
<tr>
<th>#</th>
<th>Source</th>
<th>Words</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>182</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>Bernard Canaud, Jeroen P. Kooman, Nicholas M. Selby, Maarten W. Taal et al. &quot;Dialysis-induced cardiovascular and multiorgan morbidity&quot;, Kidney International Reports, 2020</td>
<td>60</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>academic.oup.com</td>
<td>19</td>
<td>&lt;1</td>
</tr>
<tr>
<td>4</td>
<td>mts.intechopen.com</td>
<td>12</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>